Genprex (Genprex) EBIT per Share : $-23.10 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Genprex EBIT per Share?

Genprex's EBIT per Share for the three months ended in Dec. 2023 was $-4.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.10.

During the past 3 years, the average EBIT per Share Growth Rate was -3.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Genprex's EBIT per Share or its related term are showing as below:

GNPX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -122.1 Med: -14.85 Max: 21.2
Current: -3.9

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Genprex was 21.20% per year. The lowest was -122.10% per year. And the median was -14.85% per year.

GNPX's 3-Year EBIT Growth Rate is ranked worse than
59.22% of 1307 companies
in the Biotechnology industry
Industry Median: 3.4 vs GNPX: -3.90

Genprex's EBIT for the three months ended in Dec. 2023 was $-5.99 Mil.

Genprex EBIT per Share Historical Data

The historical data trend for Genprex's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex EBIT per Share Chart

Genprex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-26.64

-20.23

-17.56

-19.88

-22.72

Genprex Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-5.48	-7.50	-6.19	-5.39	-4.03

Genprex EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Genprex's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-31.076	/	1.368
=	-22.72

Genprex's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.987	/	1.487
=	-4.03

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.10

Genprex (NAS:GNPX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Genprex EBIT per Share Related Terms

Thank you for viewing the detailed overview of Genprex's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Genprex (Genprex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

2DE:Germany

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.

Executives

Catherine M Vaczy	officer: EVP & Chief Strategy Officer	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner	director, 10 percent owner, officer: Chief Executive Officer	P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar	officer: Chief Mfgr & Tech Officer	3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker	director	C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio	director	1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr.	director	1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman	officer: EVP & Chief Operating Officer	16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc.	director, 10 percent owner, officer: Chief Executive Officer	1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham	officer: Chief Operating Officer	944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth	10 percent owner	6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance	10 percent owner	8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer	officer: Chief Financial Officer	1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson	director	3001 MEANDERING RIVER COURT, AUSTIN TX 78746